Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1977 4
1979 2
1980 2
1981 4
1982 8
1983 4
1984 14
1985 12
1986 10
1987 7
1988 5
1989 7
1990 1
1991 4
1992 3
1993 3
1994 7
1995 4
1996 2
1997 4
1998 5
2000 2
2001 7
2002 2
2005 3
2006 1
2007 5
2008 1
2009 4
2010 1
2011 3
2012 5
2013 13
2014 28
2015 40
2016 32
2017 32
2018 35
2019 51
2020 59
2021 63
2022 53
2023 53
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

546 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for glucagon mr
Your search for glucoton-mr retrieved no results
Glucagon-like peptide 1 (GLP-1).
Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH. Müller TD, et al. Mol Metab. 2019 Dec;30:72-130. doi: 10.1016/j.molmet.2019.09.010. Epub 2019 Sep 30. Mol Metab. 2019. PMID: 31767182 Free PMC article. Review.
BACKGROUND: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. ...
BACKGROUND: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. ...
Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies.
Zheng D, Li N, Hou R, Zhang X, Wu L, Sundquist J, Sundquist K, Ji J. Zheng D, et al. BMC Med. 2023 Feb 3;21(1):40. doi: 10.1186/s12916-023-02753-6. BMC Med. 2023. PMID: 36737746 Free PMC article.
BACKGROUND: The ability of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to decrease certain microvascular events has called for the investigation of GLP-1 RAs against diabetic retinopathy (DR), but the evidence is limited. By combining data from observational and …
BACKGROUND: The ability of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to decrease certain microvascular events has called …
Metabolic Messengers: glucagon.
MacDonald PE, Rorsman P. MacDonald PE, et al. Nat Metab. 2023 Feb;5(2):186-192. doi: 10.1038/s42255-022-00725-3. Epub 2023 Jan 13. Nat Metab. 2023. PMID: 36639733 Review.
Plasma glucose is tightly regulated via the secretion of the two glucose-regulating hormones insulin and glucagon. Situated next to the insulin-secreting beta-cells, the alpha-cells produce and secrete glucagon-one of the body's few blood glucose-increasing hormones …
Plasma glucose is tightly regulated via the secretion of the two glucose-regulating hormones insulin and glucagon. Situated next to t …
Central and peripheral GLP-1 systems independently suppress eating.
Brierley DI, Holt MK, Singh A, de Araujo A, McDougle M, Vergara M, Afaghani MH, Lee SJ, Scott K, Maske C, Langhans W, Krause E, de Kloet A, Gribble FM, Reimann F, Rinaman L, de Lartigue G, Trapp S. Brierley DI, et al. Nat Metab. 2021 Feb;3(2):258-273. doi: 10.1038/s42255-021-00344-4. Epub 2021 Feb 15. Nat Metab. 2021. PMID: 33589843 Free PMC article.
The anorexigenic peptide glucagon-like peptide-1 (GLP-1) is secreted from gut enteroendocrine cells and brain preproglucagon (PPG) neurons, which, respectively, define the peripheral and central GLP-1 systems. ...
The anorexigenic peptide glucagon-like peptide-1 (GLP-1) is secreted from gut enteroendocrine cells and brain preproglucagon (PPG) ne …
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, Serusclat P, Violante R, Watada H, Davies M; PIONEER 3 Investigators. Rosenstock J, et al. JAMA. 2019 Apr 16;321(15):1466-1480. doi: 10.1001/jama.2019.2942. JAMA. 2019. PMID: 30903796 Free PMC article. Clinical Trial.
IMPORTANCE: Phase 3 trials have not compared oral semaglutide, a glucagon-like peptide 1 receptor agonist, with other classes of glucose-lowering therapy. ...
IMPORTANCE: Phase 3 trials have not compared oral semaglutide, a glucagon-like peptide 1 receptor agonist, with other classes of gluc …
Metabolic regulation of glucagon secretion.
Armour SL, Stanley JE, Cantley J, Dean ED, Knudsen JG. Armour SL, et al. J Endocrinol. 2023 Sep 8;259(1):e230081. doi: 10.1530/JOE-23-0081. Print 2023 Sep 1. J Endocrinol. 2023. PMID: 37523232 Free PMC article.
Canonically, alpha cells have been described in the context of glucagon's role in glucose metabolism in liver, with glucose as the primary nutrient signal regulating alpha cell function. However, current data reveal a more holistic model of metabolic signalling, inv …
Canonically, alpha cells have been described in the context of glucagon's role in glucose metabolism in liver, with glucose as …
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
Choi JG, Winn AN, Skandari MR, Franco MI, Staab EM, Alexander J, Wan W, Zhu M, Huang ES, Philipson L, Laiteerapong N. Choi JG, et al. Ann Intern Med. 2022 Oct;175(10):1392-1400. doi: 10.7326/M21-2941. Epub 2022 Oct 4. Ann Intern Med. 2022. PMID: 36191315 Free PMC article.
BACKGROUND: Guidelines recommend sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists as second-line therapy for patients with type 2 diabetes. ...
BACKGROUND: Guidelines recommend sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonis …
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Davies M, et al. JAMA. 2017 Oct 17;318(15):1460-1470. doi: 10.1001/jama.2017.14752. JAMA. 2017. PMID: 29049653 Free PMC article. Clinical Trial.
IMPORTANCE: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection. ...
IMPORTANCE: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are al …
Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients.
Allegretti JR, Kassam Z, Mullish BH, Chiang A, Carrellas M, Hurtado J, Marchesi JR, McDonald JAK, Pechlivanis A, Barker GF, Miguéns Blanco J, Garcia-Perez I, Wong WF, Gerardin Y, Silverstein M, Kennedy K, Thompson C. Allegretti JR, et al. Clin Gastroenterol Hepatol. 2020 Apr;18(4):855-863.e2. doi: 10.1016/j.cgh.2019.07.006. Epub 2019 Jul 10. Clin Gastroenterol Hepatol. 2020. PMID: 31301451 Free article. Clinical Trial.
BACKGROUND & AIMS: Studies in mice have shown that the intestinal microbiota can contribute to obesity via the anorexigenic gut hormone glucagon-like peptide 1 (GLP1) and bile acids, which affect lipid metabolism. ...
BACKGROUND & AIMS: Studies in mice have shown that the intestinal microbiota can contribute to obesity via the anorexigenic gut hormone …
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation.
McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. McLean BA, et al. Endocr Rev. 2021 Mar 15;42(2):101-132. doi: 10.1210/endrev/bnaa032. Endocr Rev. 2021. PMID: 33320179 Free PMC article. Review.
Glucagon-like peptide-1 (GLP-1) is produced in gut endocrine cells and in the brain, and acts through hormonal and neural pathways to regulate islet function, satiety, and gut motility, supporting development of GLP-1 receptor (GLP-1R) agonists for the treatment of diabete …
Glucagon-like peptide-1 (GLP-1) is produced in gut endocrine cells and in the brain, and acts through hormonal and neural pathways to …
546 results